Clinical Trial Update: Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy [Phase 2]

View source ↗

Summary

Clinical trial update indicates a Phase 2 safety and tolerability study of SPN-817 in adults with treatment-resistant epilepsy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• SPN-817 (SPN-817)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Epilepsy, Seizures, Epileptic | Phase 2 | Status: RECRUITING